유방암 환자의 항암화학요법으로 인한 말초신경병증과 삶의 질
Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Breast Cancer Patients
2
조회
0
다운로드
11
인용
0
참고문헌
키워드
초록
Abstract
Purpose: This study was performed to identify the levels of paclitaxel-containing chemotherapy-induced peripheral neuropathy (CIPN) in relation to quality of life (QOL) in patients with breast cancer. Methods: A total of 82 breast cancer patients with CIPN participated in this study. Data were collected through self-reported questionnaires containing three instruments by the European Organization for Research and Treatment of Cancer (EORTC), such as QLQ-C30 for health-related QOL, QLQ-BR23 for breast cancerrelated QOL, and QLQ-CIPN20 for CIPN. Scores from all three instruments were transformed into 0 to 100 scale. Data were analyzed using SPSS/WIN20 with descriptive statistics and Pearson’s correlations. Results: The mean score for each subscale of health-related QOL was 46.14 for global health status, 62.43 for functional scale, and 31.29 for symptom scale. The mean score for each subscale of breast cancer-related QOL was 56.55 for the functional scale and 42.06 for the symptom scale. Also, the CIPN's mean score on the sensory scale was 30.42, 24.03 on the motor scale, and 22.70 on the autonomic scale. There were significant moderate correlations between QOLs and CIPN (r ranged from -.37 to .65). Conclusion: There is a need to develop interventions for breast cancer patients to enhance their quality of life and to alleviate chemotherapy-induced peripheral neuropathy.
참고문헌 (25)
- "National cancer statistics"[URL]
- Kirsner RS, "Earlier stage at diagnosis and improved survival among Medicare HMO patients with breast cancer", J Womens Health, 19, pp.1619~1624 (2010)
- Sasane M, "Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: a review", J Support Oncol, 8(6), pp.15~21 (2010)
- Postma TJ, "The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy : the QLQ-CIPN20", Eur J Cancer, 41, pp.1135~1139 (2005)
- Visovsky C, "Putting evidence into practice : evidence-based interventions for chemotherapyinduced peripheral neuropathy", Clin J Oncol Nurs, 11(6), pp.901~913 (2007)
- Tofthagen C, "Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin", Clin J Oncol Nurs, 15(2), pp.182~188 (2011)
- Ocean AJ, "Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies", Support Care Cancer, 12, pp.619~662 (2004)
- "Taxane for adjuvant treatment of early breast cance"[URL]
- Shimozuma K, "Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy : N-SAS BC 02, a randomized clinical trial", Support Care Cancer, 20(12), pp.3355~3364 (2012)
- Wampler MA, "Case report : painful peripheral neuropathy following treatment with docetaxel for breast cancer", Clin J Oncol Nurs, 9(2), pp.189~193 (2005)
- Richardson PG, "Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib", J Clin Oncol, 24(19), pp.3113~3120 (2006)
- 김정혜, "항암화학요법으로 인한 말초신경병증을 경험하는 대장암 환자의 삶의 질", Asian Oncology Nursing, 11(3), pp.254~262 (2011), 대한종양간호학회
- Clark PG, "Effects of reiki, yoga, or meditation on the physical and psychological symptoms of chemotherapyinduced peripheral neuropathy : a randomized pilot study", J Evid Based Complement Alternat Med, 17(3), pp.161~171 (2012)
- Cavaletti G, "The chemotherapy-induced peripheral neuropathy outcome measures standardization study : from consensus to the first validity and reliability findings", Ann Oncol, 24(2), pp.454~462 (2013)
- Kim HY, "Reliability and validity of the Korean version of the EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20", Poster session presented at the meetings of the 4th Global Breast Cancer Conference, pp.10~12 (2013)
- Faul F, "Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses", Behav Res Methods, 41, pp.1149~1160 (2009)
- Fayers PM, "The EORTC QLQ-C30 scoring manual." (2001), European Organization for Research and Treatment of Cancer
- Yun YH, "Validation of the Korean version of the EORTC QLQ-C30", Qual Life Res, 13, pp.863~868 (2004)
- Yun YH, "Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer(EORTC)Breast Cancer Specific Quality of Life Questionnaire(EORTC QLQ-BR23)", Support Care Cancer, 12(6), pp.441~445 (2004)
- 곽미경(Kwak, Mi Kyong), "항암화학요법으로 인한 암환자의 말초신경병증 관련 특성과 삶의 질", Asian Oncology Nursing, 10(2), pp.231~239 (2010), 대한종양간호학회
- "Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis. Breast Cancer 2013"[URL]
- Merli F, "Quality of life assessment in elderly patients with aggressive non-Hodgkin’s lymphoma treated with anthracycline-containing regimens", Haematologica, 89(8), pp.973~978 (2005)
- Kautio A, "Burden of chemotherapy-induced neuropathy : a cross-sectional study", Support Care Cancer, 19, pp.1991~1996 (2011)
- Wolf SL, "The relationship between numbness, tingling, and shooting", burning pain in patients with chemotherapy-induced peripheral neuropathy(CIPN)as measured by the EORTC QLQ-CIPN instrument, N06CA, 2012, pp.20, 625~632
- Tofthagen C, "Falls in persons with chemotherapy-induced peripheral neuropathy", Support Care Cancer, 20, pp.583~589 (2012)